At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 619 enrolled
Drug / intervention
13-valent Pneumococcal Conjugate Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Active-Controlled, Double-blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in Spain
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Aug 29, 2006·Updated Aug 16, 2012
In Brief
A Phase 3 clinical trial evaluating 13-valent Pneumococcal Conjugate Vaccine and 7-valent Pneumococcal Conjugate Vaccine for Vaccines, Pneumococcal. Completed, enrolled 619 participants across 41 sites.
Detailed Summary
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine pediatric vaccinations in Spain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVaccines, Pneumococcal
CountriesSpain
Collaborators--
Timeline
Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2006
Enrollment StartOct 2006
Primary CompletionJul 2008
TodayJul 2026
First PostedAug 29, 2006
Enrollment StartOct 1, 2006
Primary CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 19.8 years ago
Interventions
13-valent Pneumococcal Conjugate Vaccinebiological
7-valent Pneumococcal Conjugate Vaccinebiological